Related Experiment Video

Updated: Jun 19, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Implications and problems of the Sudden Cardiac Death in Heart Failure Trial

Wataru Shimizu1, Kazuhiro Satomi

  • 1National Cardiovascular Center, Division of Cardiology, Department of Internal Medicine, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.

Future Cardiology
|October 7, 2009
PubMed

Insights

Implantable cardioverter defibrillators (ICDs) significantly reduced mortality by 23% in heart failure patients with reduced ejection fraction. This finding confirms ICDs as the standard of care for this high-risk population.

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • Congestive heart failure (CHF) with reduced left ventricular function poses a significant mortality risk.
  • Identifying effective interventions to prevent sudden cardiac death (SCD) in these patients is crucial.

Purpose of the Study:

  • To evaluate the efficacy of amiodarone versus implantable cardioverter-defibrillators (ICDs) in reducing mortality in patients with CHF.
  • To establish the role of ICDs as a standard of care for heart failure patients with impaired ejection fraction.

Main Methods:

  • The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) randomized patients with moderate-to-severe heart failure and ejection fraction < 35% to receive either amiodarone or an ICD, alongside conventional therapy.
  • Mortality rates were compared between the treatment groups and placebo.

Main Results:

  • ICDs demonstrated a significant 23% reduction in mortality compared to placebo in patients with heart failure and reduced ejection fraction.
  • The benefits of ICD therapy were consistent across ischemic and non-ischemic etiologies and for patients with NYHA Class II and III heart failure.

Conclusions:

  • Implantable cardioverter-defibrillator therapy is the established standard of care for patients with heart failure and significantly impaired left ventricular function.
  • Ongoing research is exploring adjunctive therapies and advanced devices to further improve outcomes in ICD-eligible heart failure patients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...